Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07479043 Mesenchymal stem cells (Therapeutic Solutions International) Respiratory Distress Syndrome, Acute Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07479043 clinical trial report covering Mesenchymal stem cells (Therapeutic Solutions International), Phase 3, endpoints, sponsor, geography, readout ti
Latest Hotspot
8 min read
NCT07481799 Becotatug vedotin Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07481799 clinical trial report covering Becotatug vedotin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07483736 Amoxicillin/Clavulanate Potassium Chemotherapy-Induced Febrile Neutropenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07483736 clinical trial report covering Amoxicillin/Clavulanate Potassium, Phase 3, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07482085 Efavirenz Creutzfeldt-Jakob Disease, Sporadic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07482085 clinical trial report covering Efavirenz, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07483684 Tipiracil Hydrochloride/Trifluridine Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07483684 clinical trial report covering Tipiracil Hydrochloride/Trifluridine, Phase 3, endpoints, sponsor, geography, readout timing and development whi
Latest Hotspot
8 min read
NCT07482176 Ixoberogene soroparvovec Wet age-related macular degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07482176 clinical trial report covering Ixoberogene soroparvovec, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07481786 Bevacizumab Adenocarcinoma of Lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07481786 clinical trial report covering Bevacizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07481630 Zenagamtide Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07481630 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07481981 Treprostinil palmitil Familial Primary Pulmonary Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07481981 clinical trial report covering Treprostinil palmitil, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07483632 Fingolimod Hydrochloride Multiple sclerosis relapse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07483632 clinical trial report covering Fingolimod Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07482787 Allantoin Epidermolysis Bullosa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07482787 clinical trial report covering Allantoin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07482813 Allantoin Epidermolysis Bullosa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07482813 clinical trial report covering Allantoin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.